GW takes cannabinoids into diabetes and CNS indications
This article was originally published in Scrip
Executive Summary
Following its IPO on Nasdaq in May which raised $30.4m, GW Pharmaceuticals – which develops cannabinoid-based medicines – has planned a significant amount of clinical trial activity for its pipeline in the second half of this year.